The diagnosis of infectious diseases is ineffective when the diagnostic test does not meet
one or more of the necessary standards of affordability, accessibility, and accuracy. The …

Abstract The coronavirus disease 2019 (COVID-19) has extensively promoted the
application of nucleic acid testing technology in the field of clinical testing. The most widely …

The use of microRNAs as clinical cancer biomarkers is hindered by the absence of accurate,
fast and inexpensive assays for their detection in biofluids. Here we report a one-step and …

Type VI CRISPR-Cas systems have been repurposed for various applications such as gene
knockdown, viral interference, and diagnostics. However, the identification and …

Nucleic acid detection methods based on CRISPR and isothermal amplification techniques
show great potential for point-of-care diagnostic applications. However, most current …

Biosensing based on CRISPR-Cas systems is a young but rapidly evolving technology. The
unprecedented properties of the CRISPR-Cas system provide an innovative tool for …

The COVID-19 pandemic has challenged the conventional diagnostic field and revealed the
need for decentralized Point of Care (POC) solutions. Although nucleic acid testing is …

An ideal molecular diagnostic method should be sensitive, specific, low cost, rapid, portable,
and easy to operate. Traditional nucleic acid detection methods based mainly on PCR …

Rapid, highly sensitive, and accurate virus circulation monitoring techniques are critical to
limit the spread of the virus and reduce the social and economic burden. Therefore, point-of …

For epidemic prevention and control, molecular diagnostic techniques such as field‐effect
transistor (FET) biosensors is developed for rapid screening of infectious agents, including …